Oncotarget

Research Papers:

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

Yuan Yang, Jingyi Zhou, Xiaoping Li, Lijun Zhao, Yuan Cheng, Yanying Lin, Jiaqi Wang, Lihui Wei, Yafeng Dong and Jianliu Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:115360-115369. https://doi.org/10.18632/oncotarget.23264

Metrics: PDF 499 views  |   HTML 1337 views  |   ?  


Abstract

Yuan Yang1,2,*, Jingyi Zhou1,*, Xiaoping Li1, Lijun Zhao1, Yuan Cheng1, Yanying Lin1, Jiaqi Wang1, Lihui Wei1, Yafeng Dong3 and Jianliu Wang1

1Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, China

2The First Hospital of Lanzhou University, Lanzhou, China

3Obstetrics and Gynecology Department, University of Kansas School of Medicine, Kansas City, KS, USA

*These authors have contributed equally to this work

Correspondence to:

Jianliu Wang, email: wangjianliu@pkuph.edu.cn

Keywords: endometrial cancer; gefitinib; MPA; DUSP1; targeted therapy

Received: July 14, 2017    Accepted: December 01, 2017    Published: December 15, 2017

ABSTRACT

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cell lines more effectively than MPA treatment alone. Moreover, combined treatment with Gefitinib plus MPA reduced growth of EC xenografts in Balb/c nude mice more than either Gefitinib or MPA alone. The therapeutic efficacy of combined Gefitinib plus MPA treatment was dependent on expression of dual-specificity phosphatase 1 (DUSP1). DUSP1 knockdown in Ishikawa cells treated with Gefitinib plus MPA showed greater proliferation and invasiveness than parental Ishikawa cells treated similarly. EC cells treated with the combination of Gefitinib plus MPA also showed DUSP1-dependent reductions in phospho-ERK1/2 and increases in E-Cadherin. Thus, Gefitinib appears to DUSP1-dependently enhance the therapeutic efficacy of progestin in EC cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23264